CClinicalTrials.gg
CompletedNCT06482177COATUpdated Jul 1, 2024

The COAT Trial: Cequa's Onset of Action Trial

A Phase 4 interventional study of Cyclosporine ophthalmic solution in Dry Eye, sponsored by Research Insight LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-01.

Sponsored by Research Insight LLC · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.
  • Registered 8 months after the study started (first participant enrolled Oct 2023, registered Jun 2024).
Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Cequa's Onset of Action Trial: an Investigation of CEQUA's Speed of Onset in Improving Ocular Surface Health in Dry Eye Patients

Read the detailed description

The purpose of this study is to examine the speed of onset of CEQUA ™ in improving the ocular surface among patients with dry eye.

02

Conditions studied

03

In context

Dry Eye Syndromes

1,292 studies on the registry are indexed under Dry Eye Syndromes; 191 are open to participants now.

This study's enrollment of 52 is below the median of 60 across 1,077 interventional studies indexed under Dry Eye Syndromes.

Browse Dry Eye Syndromes studies →

Lead sponsor

Research Insight LLC is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

*Patients with the following signs: Central or inferior corneal fluorescein staining defined by the Oxford Scale Reduced tear break up time (TBUT) ≤ 10 seconds.

  • Able to comprehend and sign a statement of informed consent.
  • Willing and able to complete all required postoperative visits.

Exclusion criteria

Exclusion Criteria:

  • Ocular surgery (e.g., intraocular, oculoplastic, corneal, or refractive surgical procedure) performed within the last 3 months or at any time that in the investigator's clinical judgment if it would interfere with the outcome measures of this study.
  • Clinically significant ocular trauma.
  • Active ocular Herpes simplex or Herpes Zoster infection
  • Ocular inflammation (uveitis, iritis, scleritis, episcleritis, keratitis, conjunctivitis) at the discretion of the investigator.
  • Ocular infection (e.g., viral, bacterial, mycobacterial, protozoan, or fungal infection or the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids including hordeolum/stye).
  • Active, systemic, or local disease condition that causes clinically significant ocular surface irritation such that it could interfere with the study findings.
  • Moderate to severe (Grade 2-4) allergic, vernal or giant papillary conjunctivitis.
  • Severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis)
  • Eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis).
  • Ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal epithelial defect, Grade 3 corneal fluorescein staining, map dot fingerprint dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity).
  • Participation in this trial in the same patient's fellow eye
  • Patients who are under age 18, pregnant or breastfeeding, or who may become pregnant during participation in the study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Other
    Dry Eye Disease

    Patient with dry eye disease

    Drug: Cyclosporine ophthalmic solution

Interventions

  • DrugCyclosporine ophthalmic solution

    Cyclosporine BID in the study eye

    Also known as: Cequa

06

What researchers measure

Primary outcomes

  1. Change in corneal high order aberrations (HOA)

    Change in corneal HOA

    Time frame: After 7, 14, and 28 days of treatment

Secondary outcomes

  1. Change in corneal staining

    Corneal staining

    Time frame: After 7, 14, 28 days of treatment

Other outcomes

  1. Change in best corrected visual acuity

    Best corrected visual acuity

    Time frame: After 7, 14, and 28 days of treatment

07

Study locations

1 site
  • Harvard Eye Associates
    Laguna Hills, California 92653, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06482177
Lead sponsor
Research Insight LLC
Responsible party
Sponsor
First posted
Jul 1, 2024
Start date
Oct 12, 2023
Primary completion
Jun 5, 2024
Completion
Jun 5, 2024
Last update
Jul 1, 2024

Study contacts

John Hovanesian, MD
principal investigator · Harvard Eye Associates

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion